In today’s briefing:
- Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren’s Drug
- MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
- TELO: Another Potential Breakthrough
- VNRX: Reports 3Q 2024 results. Over 110
Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren’s Drug
- Key regional partner for Veldona; a good start for Ainos’ out-licensing strategy.
- Ainos entered a strategic partnership with Taiwan Tanabe Seiyaku for Veldona in Sjogren’s syndrome.
- Under a memorandum of understanding (MOU), the collaboration aims to advance Veldona development by leveraging Taiwan Tanabe’s established expertise in drug manufacturing and Taiwan market promotion.
MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
- On November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced a strategic realignment with a name change to MetaVia Inc. (MTVA).
- The change became effective on November 29, 2024.
- We are republishing the latest research report under the MTVA ticker.
TELO: Another Potential Breakthrough
- Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.
- Preclinical tests showed that the company’s signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels.
- These results add to previous testing results showing a myriad of potential life improving and extending benefits.
VNRX: Reports 3Q 2024 results. Over 110
- Volition’s Nu.Q Vet Canine Cancer Screening Test now available in 17 countries, particularly by Antech on its Element I+ diagnostic point-of-sale platform (in the U.S., Europe, Australia, India & Singapore) and by Fujifilm Vet Systems (Japan).
- A Data Room that contains all clinical studies and other data related to Capture-PCR (human cancer detection method) and Nu.Q NETs for human sepsis has been set up to support licensing discussions and negotiations with interested parties.
- Research continues on developing biomarkers for multiple cancers in proof of concept studies.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
